Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116323 | 0.92 | KYNU (0.56) | KYNUCYP3A4ALDH1A1MAPTTSHR | |
| SCHEMBL4084753 | 0.90 | KYNU (0.48) | KYNUCYP3A4ALDH1A1MAPTTSHR | |
| SCHEMBL4097233 | 0.87 | GRM8 (0.52) | KYNUALDH1A1TSHRCA1CA2 | |
| SCHEMBL13774895 | 0.87 | GRM4 (0.53) | KYNUCYP3A4ALDH1A1MAPTTSHR | |
| SCHEMBL13774896 | 0.86 | GRM8 (0.53) | KYNUALDH1A1MAPTTSHR | |
| SCHEMBL16460533 | 0.86 | GRM8 (0.54) | KYNUALDH1A1MAPTTSHRLMNA | |
| SCHEMBL13774966 | 0.86 | GRM8 (0.53) | KYNUALDH1A1MAPTTSHR | |
| SCHEMBL16460728 | 0.85 | KYNU (0.48) | KYNUALDH1A1TSHRTP53 | |
| SCHEMBL16460736 | 0.85 | KYNU (0.48) | KYNUALDH1A1TSHRTP53 | |
| SCHEMBL4096826 | 0.84 | KYNU (0.51) | KYNUALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | P4HA1, CYP2R1, EGLN3 | KYNU 2750/4885CYP3A4 3369/4885ALDH1A1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.